U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

MedGen UID:
1791569
•Concept ID:
C5555128
•
Neoplastic Process

Definition

An aggressive B-cell non-Hodgkin lymphoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD, Rogalski M, Jacobson CA
Expert Opin Biol Ther 2019 Nov;19(11):1157-1164. Epub 2019 Jul 25 doi: 10.1080/14712598.2019.1644316. PMID: 31342797

Recent clinical studies

Etiology

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients.
Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M
Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):863-868. Epub 2022 Jul 18 doi: 10.1016/j.clml.2022.07.007. PMID: 35934632
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M
Oncotarget 2014 Sep 15;5(17):7368-80. doi: 10.18632/oncotarget.2255. PMID: 25228589Free PMC Article
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A
Br J Haematol 2014 Oct;167(2):177-84. Epub 2014 Jul 8 doi: 10.1111/bjh.13014. PMID: 25039868Free PMC Article
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R, Venugopal P, Gregory SA, O'brien T, Bogdanova E
Clin Lymphoma Myeloma 2007 May;7(6):406-12. doi: 10.3816/CLM.2007.n.019. PMID: 17621406

Diagnosis

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, Ogasawara K, Stepan L, Schusterbauer C, Rettby N, Hasskarl J, Izutsu K
Cancer Med 2022 Dec;11(24):4889-4899. Epub 2022 May 26 doi: 10.1002/cam4.4820. PMID: 35619325Free PMC Article

Therapy

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
Park C, Lee HS, Kang KW, Lee WS, Do YR, Kwak JY, Shin HJ, Kim SY, Yi JH, Lim SN, Lee JO, Yang DH, Jang H, Choi B, Lim J, Sun CH, Byun JM, Yoon SS, Koh Y
Nat Commun 2024 Mar 30;15(1):2776. doi: 10.1038/s41467-024-47198-4. PMID: 38555311Free PMC Article
Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.
Shang Y, Zhao H, Li D
Turk J Haematol 2023 Dec 5;40(4):284-285. Epub 2023 Sep 1 doi: 10.4274/tjh.galenos.2023.2023.0263. PMID: 37656047Free PMC Article
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H
Nature 2022 Sep;609(7926):369-374. Epub 2022 Aug 31 doi: 10.1038/s41586-022-05140-y. PMID: 36045296Free PMC Article
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL, Zhang A, Jung AS, Cohan D, Franklin JL
Leuk Lymphoma 2020 Sep;61(9):2103-2112. Epub 2020 Jun 16 doi: 10.1080/10428194.2020.1759055. PMID: 32546071
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P, Neelapu SS
Curr Oncol Rep 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z. PMID: 30919158

Prognosis

Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M
Oncotarget 2014 Sep 15;5(17):7368-80. doi: 10.18632/oncotarget.2255. PMID: 25228589Free PMC Article
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A
Br J Haematol 2014 Oct;167(2):177-84. Epub 2014 Jul 8 doi: 10.1111/bjh.13014. PMID: 25039868Free PMC Article

Clinical prediction guides

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H
Nature 2022 Sep;609(7926):369-374. Epub 2022 Aug 31 doi: 10.1038/s41586-022-05140-y. PMID: 36045296Free PMC Article
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, Ogasawara K, Stepan L, Schusterbauer C, Rettby N, Hasskarl J, Izutsu K
Cancer Med 2022 Dec;11(24):4889-4899. Epub 2022 May 26 doi: 10.1002/cam4.4820. PMID: 35619325Free PMC Article
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M
Oncotarget 2014 Sep 15;5(17):7368-80. doi: 10.18632/oncotarget.2255. PMID: 25228589Free PMC Article
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A
Br J Haematol 2014 Oct;167(2):177-84. Epub 2014 Jul 8 doi: 10.1111/bjh.13014. PMID: 25039868Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...